Regeneron profit, revenue beat on Eylea, Dupixent sales

(Reuters) - Regeneron Pharmaceuticals Inc's third-quarter profit and revenue topped analysts' estimates on Wednesday as demand rose for its flagship eye treatment Eylea and its recently launched eczema drug Dupixent.